Acute myeloid leukemia · 17 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ICE and ATRA Variant #01 | NPM1 | R 35 661 | — | — | — | ~2 | ~R 40 070 indirect | — |
Decitabine and Valproate Variant #01 | — | R 32 200 | 28d | — | — | ~24 | ~R 772 810 indirect | — |
DAT Variant #03 | — | R 21 422 | 9d | — | — | ~1 | ~R 21 422 indirect | — |
7+3i and Vorinostat Variant #01 Partial | — | R 21 019 | 7d | — | — | ~2 | ~R 42 038 indirect | — |
7+5i Variant #01 | — | R 20 716 | 7d | — | — | ~1 | ~R 20 716 indirect | — |
5+3i Variant #01 | — | R 18 457 | 5d | — | — | ~1 | ~R 18 457 indirect | — |
Daunorubicin monotherapy Variant #01 | — | R 12 849 | — | — | — | ~1 | ~R 12 849 indirect | — |
7+3i and Panobinostat Variant #01 Partial | — | R 12 305 | 19d | — | — | ~1 | ~R 12 305 indirect | — |
Cytarabine, Daunorubicin, Mercaptopurine, Prednisolone Variant #01 | — | R 11 388 | — | — | — | ~1 | ~R 11 388 indirect | — |
5+3d Variant #01 | — | R 10 793 | 5d | — | — | ~1 | ~R 10 793 indirect | — |
HAD Variant #01 Partial | — | R 8 510 | 7d | — | — | ~1 | ~R 8 510 indirect | — |
VAMP (Amethopterin) Variant #01 | — | R 7 598 | 42d | — | — | ~1 | ~R 7 598 indirect | — |
Cytarabine, Daunorubicin, Vincristine Variant #02 | — | R 7 326 | — | — | — | ~2 | ~R 14 652 indirect | — |
7+3d Variant #01 | — | R 6 538 | — | — | 15.1 mo | 2 | R 13 076 PFS proxy | 11 |
5+2d Variant #01 | — | R 6 360 | 5d | — | — | ~1 | ~R 6 360 indirect | — |
Cytarabine, Doxorubicin, Vincristine, Prednisolone Variant #01 | — | R 3 778 | — | — | — | ~2 | ~R 3 816 indirect | — |
Cytarabine and Etoposide Partial | NPM1 | — | — | — | — | — | — | — |
17 of 17 regimens shown